Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced positive results from studies of a nasal anti-CD3 monoclonal antibody in traumatic spinal cord injury (SCI).
SCI represents a major global health concern with significant effects on mortality and long-term disability, the company said in a statement on Thursday.
The inflammatory response driven by microglia plays a key role in SCI progression, it added.
In the studies, a preclinical model of SCI treated with nasal anti-CD3 demonstrated notable improvements in motor function, highlighting the potential of this approach to address the challenges of spinal cord injuries.
“Our pre-clinical findings underscore the pivotal role of nasal anti-CD3 in modulating microglial inflammation associated with spinal cord injury,” said Dr Howard Weiner, chairman of Tiziana’s Scientific Advisory Board.
Ivor Elrifi, Tiziana CEO, highlighted the strategic implications of the study results.
"We are swiftly advancing towards expanding our nasal foralumab technology from successful applications in neurologic diseases like secondary progressive multiple sclerosis to now encompass spinal cord injury,” Elrifi said.
“This underscores our commitment to pioneering treatments that address significant unmet medical needs."
Investors welcomed the update, with Tiziana stock up 12% shortly following the release of the update.